Macrophage Targeting pH Responsive Polymersomes for Glucocorticoid Therapy<br />

Data de publicació

2024-11-16T10:04:45Z

2024-11-16T10:04:45Z

2019-11-15

2024-11-16T10:04:45Z

Resum

Glucocorticoid (GC) drugs are the cornerstone therapy used in the treatment of inflammatory diseases. Here, we report pH responsive poly(2-methacryloyloxyethyl phosphorylcholine)–poly(2-(diisopropylamino)ethyl methacrylate) (PMPC–PDPA) polymersomes as a suitable nanoscopic carrier to precisely and controllably deliver GCs within inflamed target cells. The in vitro cellular studies revealed that polymersomes ensure the stability, selectivity and bioavailability of the loaded drug within macrophages. At molecular level, we tested key inflammation-related markers, such as the nuclear factor-κB, tumour necrosis factor-α, interleukin-1β, and interleukin-6. With this, we demonstrated that pH responsive polymersomes are able to enhance the anti-inflammatory effect of loaded GC drug. Overall, we prove the potential of PMPC–PDPA polymersomes to efficiently promote the inflammation shutdown, while reducing the well-known therapeutic limitations in GC-based therapy.

Tipus de document

Article


Versió publicada

Llengua

Anglès

Publicat per

MDPI

Documents relacionats

Reproducció del document publicat a: https://doi.org/10.3390/pharmaceutics11110614

Pharmaceutics, 2019, vol. 11, num.11, p. 614

https://doi.org/10.3390/pharmaceutics11110614

Citació recomanada

Aquesta citació s'ha generat automàticament.

Drets

cc-by (c) Gouveia, V.M. et al., 2019

http://creativecommons.org/licenses/by/4.0/

Aquest element apareix en la col·lecció o col·leccions següent(s)